Cognito Therapeutics Stock

Cognito Therapeutics is a neurotechnology company that is developing disease-modifying treatments for CNS illnesses.

Sign up today and learn more about Cognito Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Cognito Therapeutics Stock

Cognito Therapeutics is a clinical-stage neurotechnology business focused on creating disease-modifying pharmaceutical methods for the treatment of neurodegenerative illnesses. Li-Huei Tsai and Ed Boyden, MIT Professors, and scientific founders, created its non-invasive neuromodulation platform. The Company's primary therapy is now being studied in a pivotal study for Alzheimer's Disease and has been designated as a Breakthrough Device by the FDA.

Funding History

June 2022$53.3M
March 2023$73.0M



Zach Malchano

VP, BD and Strategic Partnerships

Martin Williams

Chief Executive Officer

Brent Vaughan


Mihaly Hajos

Board of Directors

Richard Kuntz

VP of Products

Divya Dhar

Board of Directors

Helen Liang

Chief Commercial Officer

Everett Crosland


Li-Huei Tsai


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: